1. Signaling Pathways
  2. Immunology/Inflammation
  3. PGE synthase

PGE synthase

Prostaglandin E synthase

PGE synthase (Prostaglandin E synthase), which converts cyclooxygenase (COX)-derived prostaglandin H2 (PGH2) to PGE2, is known to comprise a group of at least three structurally and biologically distinct enzymes. There are membrane-associated PGES (mPGES)-1, mPGES-2, and cytosolic PGES (cPGES).

mPGES-1 is a perinuclear protein that is markedly induced by proinflammatory stimuli and downregulated by anti-inflammatory glucocorticoids as in the case of COX-2. It is functionally coupled with COX-2 in marked preference to COX-1. mPGES-2 is synthesized as a Golgi membrane-associated protein, and the proteolytic removal of the N-terminal hydrophobic domain leads to the formation of a mature cytosolic enzyme. This enzyme is rather constitutively expressed in various cells and tissues and is functionally coupled with both COX-1 and COX-2. cPGES is constitutively expressed in a wide variety of cells and is functionally linked to COX-1 to promote immediate PGE2 production.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0890A
    Zomepirac
    Inhibitor
    Zomepirac (McN-2783-21-98) is a potent prostaglandin biosynthesis inhibitor. Zomepirac is a non-steroidal anti-inflammatory drug (NSAID). Zomepirac can cause immune-mediated liver injury.
    Zomepirac
  • HY-W587743
    N1-Acetyl-5-methoxykynuramine hydrochloride
    Inhibitor
    N1-Acetyl-5-methoxykynuramine (AMK) hydrochloride is an active metabolite of the neurohormone melatonin (HY-B0075). N1-Acetyl-5-methoxykynuramine hydrochloride (200 µM) effectively scavenges singlet oxygen (ROS).1 It also inhibits the production of prostaglandin E2 (PGE2) and prostaglandin D2 (PGD2) induced by epinephrine and arachidonic acid in a concentration- and time-dependent manner, and suppresses the increase in COX-2 levels induced by LPS (HY-D1056) in RAW 264.7 macrophages at a concentration of 500 µM. In a mouse model of Parkinson's disease induced by MPTP (HY-15608), N1-Acetyl-5-methoxykynuramine hydrochloride (20 mg/kg) reduces the increase in lipid peroxidation in the cytosol and mitochondria of the substantia nigra and striatum. N1-Acetyl-5-methoxykynuramine hydrochloride can be used in research on metabolic and neurological diseases
    N1-Acetyl-5-methoxykynuramine hydrochloride
  • HY-13988R
    AT-56 (Standard)
    Inhibitor
    AT-56 (Standard) is the analytical standard of AT-56. This product is intended for research and analytical applications. AT-56 is a potent, selective and orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS), with an IC50 of 95 μM and Ki of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD2.
    AT-56 (Standard)
  • HY-30235
    Benzydamine
    Benzydamine is an orally administered prostaglandin synthesis inhibitor that has anti-inflammatory, analgesic, antipyretic, and antibacterial properties. Benzydamine can inhibit TNF-α, stabilize cell membranes, and reduce oxidative stress within cells.
    Benzydamine
  • HY-B0336R
    Pranoprofen (Standard)
    Inhibitor
    Pranoprofen (Standard) is the analytical standard of Pranoprofen. This product is intended for research and analytical applications. Pranoprofen is a non-steroidal anti-inflammatory agent (NSAID) for the research of keratitis or other ophthalmology diseases. Pranoprofen inhibit COX-1 and COX-2 enzymes, thus blocking arachidonic acid converted to eicosanoids and reducing prostaglandins synthesis.
    Pranoprofen (Standard)
Cat. No. Product Name / Synonyms Application Reactivity